Total Funding
35
35
Total FundingPost-IPO Equity raised
Growth Score
-6 pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
46048
Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.
- Troy Lister: Senior Vice President Research & Early DevelopmentPast Role: Spero Therapeutics, VP of Research and Development
- Issi Rozen: Co-FounderPast Role: Broad Institute, Chief Business Officer
About the Company
Verve Therapeutics develops genetic medicines that target cardiovascular diseases through innovative therapies. The company focuses on creating treatments that address the genetic causes of these conditions, aiming to transform how cardiovascular diseases are managed. As a clinical-stage organization, Verve is engaged in advancing its product
candidates through rigorous research and development processes. The company emphasizes its commitment to improving patient outcomes by leveraging genetic insights to develop effective solutions. Verve Therapeutics continues to evolve in the field of genetic medicine, contributing to the future of cardiovascular health.
